Traphagen Investment Advisors LLC Sells 265 Shares of Johnson & Johnson (NYSE:JNJ)

Traphagen Investment Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,218 shares of the company’s stock after selling 265 shares during the quarter. Traphagen Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,478,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Fred Alger Management LLC lifted its holdings in shares of Johnson & Johnson by 6.1% in the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after buying an additional 2,488 shares during the period. Dark Forest Capital Management LP purchased a new stake in Johnson & Johnson during the second quarter worth $223,000. MBB Public Markets I LLC boosted its position in Johnson & Johnson by 1,827.5% during the second quarter. MBB Public Markets I LLC now owns 181,395 shares of the company’s stock valued at $26,513,000 after purchasing an additional 171,984 shares in the last quarter. Marathon Capital Management grew its stake in Johnson & Johnson by 3.3% in the second quarter. Marathon Capital Management now owns 29,668 shares of the company’s stock valued at $4,336,000 after purchasing an additional 940 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Johnson & Johnson by 0.3% in the second quarter. The Manufacturers Life Insurance Company now owns 2,686,122 shares of the company’s stock worth $392,603,000 after purchasing an additional 7,107 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JNJ. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Thursday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday. Raymond James cut their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Wells Fargo & Company lowered their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Johnson & Johnson Stock Up 0.1 %

Shares of JNJ stock opened at $146.76 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a 50 day moving average of $147.99 and a 200 day moving average of $155.98. The stock has a market cap of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22,438,500 billion. During the same period in the prior year, the firm posted $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.